Harry G Brittain

Title: Harry G Brittain: Inventor and Collaborator in the World of Pharma Innovations

Introduction:

In the realm of pharmaceutical innovations and patents, Harry G Brittain has made significant contributions through his inventive mind and collaborative approach. With his base in Milford, NJ (US), Brittain has actively worked with various companies, research institutions, and fellow inventors to drive advancements in pharmaceutical compositions and manufacturing methods.

Latest Patents:

With an impressive track record of 24 patents, Brittain continues to engage in groundbreaking research and development. Two of his most recent patents are worth highlighting:

1. Amorphous onapristone compositions and methods of making the same:

This patent focuses on amorphous forms of onapristone, a pharmaceutical compound, and their innovative manufacturing techniques. The patent outlines how the amorphous forms can be characterized based on their unique X-ray powder diffraction patterns and other distinguishing properties.

2. Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine:

In this patent, Brittain explores cocrystal compositions involving metoprolol and dabigatran bases. The patent further delves into the compatibility of these bases with specific enantiomers of theanine, presenting opportunities for enhanced pharmaceutical formulations.

Career Highlights:

Throughout his career, Brittain has consistently demonstrated a knack for innovation and problem-solving. His expertise lies in the field of pharmaceutical sciences, where he has contributed significantly to improving drug delivery systems, analytical techniques, and formulation design.

Collaborations:

Brittain's success can be attributed in part to his collaborations with notable companies and individuals from the pharmaceutical industry. Some of the companies he has worked with include:

1. Theaprin Pharmaceuticals Inc.:

Brittain collaborated with Theaprin Pharmaceuticals Inc., a leading organization dedicated to the development of therapeutic drugs. His association with this company highlights his commitment to translating his research into real-world applications.

2. Alkermes Pharma Ireland Limited (Alkermes):

Another noteworthy collaboration exists between Brittain and Alkermes, a global biopharmaceutical company. Alkermes specializes in the development of innovative medicines for the treatment of widespread diseases, mental health disorders, and addiction.

Some of his coworkers deemed instrumental to his achievements include Philip V Felice and David A Dickason. Their combined expertise and collaborative efforts have undoubtedly contributed to the success of numerous projects.

Conclusion:

Harry G Brittain stands as an exemplar in the field of pharmaceutical innovations and patents. With an impressive patent portfolio and a reputation for collaboration, Brittain exemplifies the importance of partnership and creative problem-solving in driving advancements within the pharmaceutical industry. His contributions to the development of amorphous drug forms and cocrystal compositions showcase his commitment to enhancing drug efficacy and patient outcomes.